Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456571 · ClinicalTrials.gov registry record
CTC Immune Checkpoint
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 38
- Enrollment target
NCT02456571: Completed study, sponsored by Duke University.
NCT02456571 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02456571 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking CD45 expression.
Interventions
- DEVICE CTC biomarker expression prevalence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-06-13 |
What the finished NCT02456571 record still lists
NCT02456571 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CTC biomarker expression prevalence is the first listed.
NCT02456571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02456571 about?
NCT02456571 is a clinical study titled "CTC Immune Checkpoint". This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking...
What is the current status of trial NCT02456571?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2016-11. Estimated completion is 2019-06-13.
What interventions are being tested in trial NCT02456571?
The interventions under investigation include: CTC biomarker expression prevalence (DEVICE).
Who is sponsoring clinical trial NCT02456571?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia